Andrew Dauber, M.D., will present positive results from his investigator-sponsored Phase 2 study of VOXZOGO in children with hypochondroplasia. The annualized growth velocity (AGV) increased from 5.12 ...
New data from a study in Japan showed strong treatment adherence with VOXZOGO in children with achondroplasia under the age of 3, with no reported treatment-related adverse events nor any dose ...
Please provide your email address to receive an email when new articles are posted on . Infigratinib increased annualized height velocity for children with achondroplasia in a phase 2 trial. BridgeBio ...
SAN RAFAEL, Calif., Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO ® ...
Until an ultrasound scan at 20 weeks, Samantha Anderson’s second pregnancy had been going according to plan. That scan revealed that her baby had some excess fluid in their skull. The physician wasn’t ...
COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback